Celator Pharmaceuticals Soars 300% On Positive Phase 3 Results In High-Risk AML Patients
March 15, 2016 at 04:48 AM EDT
In after-hours trading on Monday shares of Celator Pharmaceuticals soared more than 300% as the company announced positive phase 3 results in a trial with patients with high-risk acute myeloid leukemia.
